ClearPoint Neuro (CLPT): Director received 315 shares at $21.79

Accepted by SEC EDGAR 10/02/2025 - 07:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. (CLPT) reported an insider issuance to director Pascal E. R. Girin: on 10/01/2025 the company issued 315 shares of common stock at a price equal to the closing market price on 9/30/2025, $21.79, as payment of fees under the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan and the Non-Employee Director Compensation Plan. Following the issuance, the reporting person beneficially owns 96,949 shares directly. The Form 4 was signed by an attorney under power of attorney and filed on 10/02/2025.

Positive

• 315 shares issued were paid as director compensation under the company's 2013 Incentive Compensation Plan
• Reporting person now directly holds 96,949 shares following the issuance

Negative

• None.

Insider Trade Summary

Grant/Award: 315 shares

Grant/Award 1 txn

Insider Girin Pascal E R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	315	$21.79	$7K

Holdings After Transaction: Common Stock — 96,949 shares (Direct)

Holdings Before and After: Common Stock, 96,634 to 96,949 shares (Direct)

Footnotes (1)

1. F1. These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction was reported for ClearPoint Neuro (CLPT)?

The Form 4 reports issuance of 315 shares of common stock to director Pascal E. R. Girin on 10/01/2025.

At what price were the shares issued to the director?

The shares were issued at the issuer's closing common stock price on 9/30/2025, which was $21.79 per share.

Why were the shares issued to the reporting person?

The shares were issued as payment of fees owed under the issuer's Non-Employee Director Compensation Plan, as amended and restated.

How many shares does the reporting person own after the transaction?

After the issuance, the reporting person beneficially owns 96,949 shares (direct ownership).

Who signed the Form 4 filing?

The Form 4 was signed by Danilo D'Alessandro by power of attorney for Pascal E. R. Girin and dated 10/02/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Girin Pascal E R

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		A		315	A	$21.79(1)	96,949	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.

	/s/ Danilo D'Alessandro, by Power of Attorney for Pascal E. R. Girin	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.